{"entity":{"type":"insider","cik":"0001265783","url":"/insider/0001265783","json_url":"/insider/0001265783.json","name":"AKER HAZEL M","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":7,"first":"2003-11-06","last":"2020-07-23","span_basis":"filed_date"},"name_variants":[{"name":"AKER HAZEL M","source":"filing","n_filings":7,"first_seen":"2003-11-06","last_seen":"2020-07-23"}],"transactions":[{"id":3090206,"accession":"0001209191-20-043496","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-043496","line_url":"/filing/0001209191-20-043496#line-1","is_derivative":false,"issuer_cik":"0001260990","issuer_name":"Oncternal Therapeutics, Inc.","issuer_ticker":"ONCT","issuer_name_source":null,"issuer_url":"/issuer/0001260990","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (Legal Counsel)","role_mark":"O","role_mark_label":"Officer (Legal Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Legal Counsel","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":41972.0,"shares_display":"41,972","price_per_share":2.3825,"price_display":"2.38","price_state":"stated","total_value":99998.29,"total_display":"99,998.29","total_whole":"99,998","shares_owned_after":46987.0,"shares_owned_after_display":"46,987","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-21","filed_date":"2020-07-23","scope":"insider"},{"id":4897913,"accession":"0001209191-13-057711","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-057711","line_url":"/filing/0001209191-13-057711#line-2","is_derivative":false,"issuer_cik":"0001265783","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001265783","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (SVP, GC & Secretary)","role_mark":"O","role_mark_label":"Officer (SVP, GC & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, GC & Secretary","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13014.0,"shares_display":"13,014","price_per_share":8.76,"price_display":"8.76","price_state":"stated","total_value":114002.64,"total_display":"114,002.64","total_whole":"114,003","shares_owned_after":3745.0,"shares_owned_after_display":"3,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-12-16","filed_date":"2013-12-18","scope":"insider"},{"id":4568129,"accession":"0001209191-13-052924","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-13-052924","line_url":"/filing/0001209191-13-052924","is_derivative":false,"issuer_cik":"0001265783","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001265783","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (SVP, GC & Secretary)","role_mark":"O","role_mark_label":"Officer (SVP, GC & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, GC & Secretary","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52056.0,"shares_display":"52,056","price_per_share":7.405,"price_display":"7.40","price_state":"stated","total_value":385474.68,"total_display":"385,474.68","total_whole":"385,475","shares_owned_after":29773.0,"shares_owned_after_display":"29,773","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-11-15","filed_date":"2013-11-18","scope":"insider","n_lines":2},{"id":4425239,"accession":"0001209191-13-037649","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-037649","line_url":"/filing/0001209191-13-037649#line-2","is_derivative":false,"issuer_cik":"0001265783","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001265783","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (SVP, GC & Secretary)","role_mark":"O","role_mark_label":"Officer (SVP, GC & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, GC & Secretary","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6507.0,"shares_display":"6,507","price_per_share":7.81,"price_display":"7.81","price_state":"stated","total_value":50819.67,"total_display":"50,819.67","total_whole":"50,820","shares_owned_after":3745.0,"shares_owned_after_display":"3,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-22","filed_date":"2013-07-23","scope":"insider"},{"id":5306136,"accession":"0001209191-13-037007","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-13-037007","line_url":"/filing/0001209191-13-037007#line-2","is_derivative":false,"issuer_cik":"0001265783","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001265783","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (SVP, GC & Secretary)","role_mark":"O","role_mark_label":"Officer (SVP, GC & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, GC & Secretary","security_title":"common stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6508.0,"shares_display":"6,508","price_per_share":7.3417,"price_display":"7.34","price_state":"stated","total_value":47779.7836,"total_display":"47,779.78","total_whole":"47,780","shares_owned_after":3745.0,"shares_owned_after_display":"3,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-15","filed_date":"2013-07-17","scope":"insider"},{"id":8835379,"accession":"0001209191-11-057742","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-11-057742","line_url":"/filing/0001209191-11-057742#line-1","is_derivative":false,"issuer_cik":"0001265783","issuer_name":"CADENCE PHARMACEUTICALS INC","issuer_ticker":"CADX","issuer_name_source":null,"issuer_url":"/issuer/0001265783","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (SVP, GC & Secretary)","role_mark":"O","role_mark_label":"Officer (SVP, GC & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, GC & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":4.1621,"price_display":"4.16","price_state":"stated","total_value":41621.0,"total_display":"41,621.00","total_whole":"41,621","shares_owned_after":3745.0,"shares_owned_after_display":"3,745","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-11-21","filed_date":"2011-11-22","scope":"insider"},{"id":85477,"accession":"0001209191-03-029025","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-03-029025","line_url":"/filing/0001209191-03-029025#line-1","is_derivative":false,"issuer_cik":"0001131907","issuer_name":"CANCERVAX CORP","issuer_ticker":"CNVX","issuer_name_source":null,"issuer_url":"/issuer/0001131907","owner_cik":"0001265783","owner_name":"AKER HAZEL M","owner_display_name":"AKER HAZEL M","owner_url":"/insider/0001265783","role":"Officer (Sr. VP, General Counsel)","role_mark":"O","role_mark_label":"Officer (Sr. VP, General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Sr. VP, General Counsel","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":300.0,"shares_display":"300","price_per_share":12.0,"price_display":"12.00","price_state":"stated","total_value":3600.0,"total_display":"3,600.00","total_whole":"3,600","shares_owned_after":40072.0,"shares_owned_after_display":"40,072","ownership_form":"D","is_10b5_1":null,"transaction_date":"2003-11-04","filed_date":"2003-11-06","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001260990","name":"Oncternal Therapeutics, Inc.","url":"/issuer/0001260990","role":"Officer (Legal Counsel)","n_filings":1,"first_seen":"2020-07-23","last_seen":"2020-07-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001333248","name":"CADENCE PHARMACEUTICALS INC","url":"/issuer/0001333248","role":"Officer (SVP, GC & Secretary)","n_filings":5,"first_seen":"2011-11-22","last_seen":"2013-12-18"},{"type":"issuer","type_label":"ISSUER","cik":"0001131907","name":"CANCERVAX CORP","url":"/issuer/0001131907","role":"Officer (Sr. VP, General Counsel)","n_filings":1,"first_seen":"2003-11-06","last_seen":"2003-11-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001265783","retrieved_at":"2026-08-23T01:07:52+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}